Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
First all-oral XDR-TB drug regimen trial launches in South Africa

The regimen is comprised of bedaquiline, which received provisional approval from the U.S. Food and Drug Administration in 2013 to treat drug-resistant tuberculosis, pretomanid a new type of antibacterial drug, and linezolid which is used off-label to treat TB.

Published
15 May 2015
From
Science Speaks
WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others.

Published
11 May 2015
From
World Health Organization
High-dose rifampicin may shorten time to TB clearance

A combination regimen containing high-dose rifampicin (also known as rifampin) was associated with faster tuberculosis (TB) bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and

Published
13 April 2015
By
Liz Highleyman
End stigmatizing language in tuberculosis research and practice

Traditional terms invoke metaphors of transgression and punishment rather than of dignity and cure. Phrases such as “treatment defaulter” and “initial defaulter” apply the moral judgment of loan nonpayment to describe patients who stop treatment or never start it. Other phrases, such as “tuberculosis suspect,” treat patients as if they had committed a crime.

Published
07 April 2015
From
EATG / BMJ
Ukraine: Concurrent treatment for HIV/TB co-infection breaks up “deadly alliance”

USAID funded MEASURE Evaluation to initiate an impact evaluation in Ukraine for two TB programmatic priorities: Improving integration of TB and HIV services to reduce mortality through early diagnosis and treatment for co-infected patients; and providing social support services to improve TB treatment adherence.

Published
30 March 2015
From
Science Speaks
Final fight pays off, XXDR-TB & HIV patient cured

Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

Published
24 March 2015
From
DNAIndia
Screening for cryptococcal meningitis and adherence support reduce mortality among people starting ART in Africa

Screening and treatment for cryptococcal meningitis combined with a short period of adherence support has the potential to significantly reduce mortality rates among people with very low

Published
24 March 2015
By
Michael Carter
Decline in U.S. Tuberculosis Rates Slows: CDC

As health officials in Kansas struggle with an outbreak of tuberculosis at a local high school, federal officials reported Thursday that the annual decline in U.S. cases is slowing.

Published
20 March 2015
From
HealthDay
MSF: More than a quarter of MDR-TB cases in Swaziland not caught by “front line of defense” in fighting the disease

The nonprofit medical humanitarian organization Médecins Sans Frontières is recommending that all patients in Swaziland who have tested positive for TB, but rapid molecular testing has found negative for drug-resistance undergo further testing, following findings that a mutation has made more than a quarter of multidrug-resistant strains undetectable by the widely used test.

Published
20 March 2015
From
Science Speaks
Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

Published
18 March 2015
From
Lancet (free registration required)
← First12345...89Next →

Filter by country